Syngeneic Spleen Cells In Allogeneic Bone Marrow Transplantation In Applied Research

Allogeneic bone marrow transplantation (alloBMT) provides potential life-saving therapy for a variety of inherited and acquired diesease of the hematopoietic system. While results has been encouraging, several problems remain to impede its more wide application as a rutine clinical arrangement.The histocompatibility complex (MHC) barriers between don-nor and recipient trigger the the sequence of events of GVHD, which is responsible for 25 — 30% mortality in unmanipulated alloBMT even when the modern immuno-suppressive drugs is used, and therefore impose a strict requirement for HLA indentical bone marrow donnor. Though this problem can be avoided by T cell depletion of allogeneic bone marrow, such depletion has brought with it increased failure of allografment. Moreever, the GVL effect often associated with GVHD is reduced by T cell depletion. Thus, development of a regimen which retains allogeneic T cells with their anti-lenkemic effects while preventing lethal GVHD caused by administration of such cells would be desirable.According to the immunologic theory, GVHD and GVL are both caused by cell immue responses of donnor T lymphocytes against host normal cells and tumor cells respectively, sharing common process of immureaction which involves the recognization of recipient MHC, proliferation and differentiation of T cell clones responsible.